

**Coalesix Honors Academic Excellence at 2005 MGMS international meeting in Dublin.**

CAMBRIDGE, MA and DUBLIN, IRELAND, September 12, 2005 --- [Coalesix Inc.](#), in conjunction with the Molecular Graphics and Modeling Society (MGMS), are pleased to announce the awarding of two international student travel scholarships. The scholarships are designed to foster student participation at the MGMS international meeting held September 11-14 in Trinity College Dublin, Ireland.

All students traveling from abroad to Dublin and presenting posters at the conference were eligible for consideration. A committee composed of the local organizing committee for the MGMS international meeting and Coalesix, reviewed all student poster abstracts submitted on the basis of content and relevance of the abstract. Formal presentation of the awards was made during the gala dinner by Jim Wikel, CTO of Coalesix.

Dr David Lloyd of Trinity College Dublin, heading the local organizing committee for the MGMS meeting, said "We are delighted to have Coalesix supporting this year's meeting by creating the two international scholarships. Awarding academic excellence is an excellent way to motivate students to get involved in our society."

The winners of the Academic Excellence Awards are:

**Peter Kolb**, University of Zurich for "*Identifying and Selecting Fragments to Dock Flexible Ligands*"

**Mari L. DeMarco**, University of Washington for "*Mapping the Early Steps in Amyloidosis of the Prion Protein*".

"Coalesix is very happy to have the opportunity to encourage the participation of young scientists at the MGMS meeting", said Jim Wikel, Chief Technical Officer of Coalesix. "We feel it is vital to encourage early student involvement in scientific organizations."

About Coalesix

Headquartered in Cambridge, MA Coalesix focuses on the development and commercialization of technology to improve the efficiency of drug discovery through the use of its Mobius Candidate Design Environment (CDE). Mobius offers drug discovery organizations the ability to maximize the return on all of their Lead Optimization/Lead Generation efforts and resources while at the same time helping overcome the lead-to-candidate bottleneck. Mobius fosters interactions between computational and medicinal chemistry to produce a novel approach to address the challenges of Lead Optimization/Lead Generation in order to enable faster identification of more potential drug candidates.

More information on Mobius and Coalesix can be obtained by contacting Bill Hayden, SVP, at: (514) 895 2455.